UniDab based CAR-T therapeutic
/ Amgen, Roche
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 23, 2020
Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies
(GlobeNewswire)
- "Teneobio, Inc...announced today that in 2020, Poseida exercised four options to commercial licenses for Teneobio human heavy chain only domain antibodies, UniDabs®, to develop novel CAR T therapies...Teneobio Inc. receives commercial licensing fees for these milestones and is eligible to receive future research, development and regulatory milestone payments per UniDab candidate, with total potential earnings of over $250 million for CAR-T therapies developed by Poseida. Teneobio would also receive royalties on worldwide net sales of each CAR-T therapy."
Commercial • Oncology
1 to 1
Of
1
Go to page
1